↓ Skip to main content

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer

Overview of attention for article published in Breast Cancer Research, June 2009
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

googleplus
1 Google+ user

Citations

dimensions_citation
61 Dimensions

Readers on

mendeley
57 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer
Published in
Breast Cancer Research, June 2009
DOI 10.1186/bcr2328
Pubmed ID
Authors

Fiona M Foster, Thomas W Owens, Jolanta Tanianis-Hughes, Robert B Clarke, Keith Brennan, Nigel J Bundred, Charles H Streuli

Abstract

Inhibitor of apoptosis (IAPs) proteins are a family of proteins that can block apoptosis in normal cells and have been suggested to cause resistance to apoptosis in cancer. Overexpression of oncogenic receptor tyrosine kinases is common in breast cancer; in particular 20% of all cases show elevated Her2. Despite clinical success with the use of targeted therapies, such as Trastuzumab, only up to 35% of Her2-positive patients initially respond. We reasoned that IAP-mediated apoptosis resistance might contribute to this insensitivity to receptor tyrosine kinase therapy, in particular ErbB antagonists. Here we examine the levels of IAPs in breast cancer and evaluate whether targeting IAPs can enhance apoptosis in response to growth factor receptor antagonists and TRAIL.

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Iran, Islamic Republic of 1 2%
Spain 1 2%
United States 1 2%
Unknown 54 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 32%
Student > Ph. D. Student 10 18%
Other 5 9%
Student > Bachelor 5 9%
Student > Master 4 7%
Other 9 16%
Unknown 6 11%
Readers by discipline Count As %
Agricultural and Biological Sciences 27 47%
Medicine and Dentistry 7 12%
Biochemistry, Genetics and Molecular Biology 6 11%
Chemistry 2 4%
Computer Science 1 2%
Other 5 9%
Unknown 9 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 November 2016.
All research outputs
#8,139,950
of 12,978,654 outputs
Outputs from Breast Cancer Research
#1,051
of 1,467 outputs
Outputs of similar age
#80,212
of 151,475 outputs
Outputs of similar age from Breast Cancer Research
#18
of 24 outputs
Altmetric has tracked 12,978,654 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,467 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 151,475 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.